
|Slideshows|June 28, 2018
ADA 2018: CV Benefits of SGLT-2 Inhibitors
Author(s)Kenneth J. Bender, PharmD, MA
Three studies at ADA 2018 highlight the current track record of SGLT-2is in reducing CV-related morbidity and mortality.
Advertisement
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Patient Care Online
1
10 Questions on The Holiday Spirit
2
Adult Stimulant Use Accounts for Most Recent Growth in ADHD Prescribing in Canada
3
Retatrutide Achieves Up to 28.7% Weight Loss and Marked Knee Pain Reduction in Phase 3 TRIUMPH-4 Trial
4
FDA Clears First At-Home Brain-Stimulation Device for Major Depression
5



















































































































































































































































































